D. Wilson

Prognostic and predictive value of VEGF, sVEGFR-2 and CEA in mCRC studies comparing cediranib, bevacizumab and chemotherapy

P. Hoff, S. Morgan, J. Jürgensmeier, 2013, British Journal of Cancer.

Phase I and pharmacological study of the novel aurora kinase inhibitor AZD1152.

J. Schellens, J. Beijnen, E. Voest, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

1296P BLU-945, a highly potent and selective 4th generation EGFR TKI for the treatment of EGFR T790M/C797S resistant NSCLC

K. Hoeflich, B. Cho, T. Guzi, 2020 .

Association of baseline CEA, VEGF, and soluble VEGF receptor-2 with treatment outcomes in two randomized phase III trials of cediranib in metastatic colorectal cancer (mCRC).

P. Hoff, L. Pike, S. Morgan, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Clinical evaluation of AZD1152, an i.v. inhibitor of Aurora B kinase, in patients with solid malignant tumors.

J. Schellens, David M. Wilson, E. Voest, 2011, Annals of oncology : official journal of the European Society for Medical Oncology.

Abstract 1234: The novel FGFR4-selective inhibitor INCB062079 is efficacious in models of hepatocellular carcinoma harboring FGF19 amplification

X. Wen, M. Stubbs, P. Scherle, 2017 .